LAUSR

HS: hidradenitis suppurativa THRLBCL: T-cell/histiocyte-rich large B-cell lymphoma INTRODUCTION Hidradenitis suppurativa (HS), psoriasis, and vitiligo are chronic, immune-mediated skin diseases with a significant quality-of-life burden. Individuals with these conditions are thought to be at increased risk of lymphoma, and several cases have been reported in the context of adalimumab treatment, raising concern for its use in at-risk patients. The specific mechanisms underlying the link between chronic inflammatory states and neoplastic transformation are largely unknown, andmost data on the topic come from cases outside of dermatology (ie, rheumatoid arthritis, ulcerative colitis). We present the unusual case of a patient with HS, psoriasis, and vitiligo on long-standing treatment with adalimumab who went on to have T-cell/histiocyte-rich large Bcell lymphoma (THRLBCL) and evaluate the factors that led to this pathologic condition.